Patents by Inventor Susruta Majumdar

Susruta Majumdar has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Mitragynine analogs for the treatment of pain, mood disorders and substance use disorders
    Patent number: 11760758
    Abstract: The present invention provides a compound having the structure: or a pharmaceutically acceptable salt or ester thereof, and a method of treating a subject afflicted with pain, a depressive disorder, a mood disorder or an anxiety disorder by administering the compound to the subject.
    Type: Grant
    Filed: February 16, 2021
    Date of Patent: September 19, 2023
    Assignees: THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK, THE RESEARCH FOUNDATION FOR MENTAL HYGIENE, INC., SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH
    Inventors: Andrew C. Kruegel, Dalibor Sames, Srijita Bhowmik, Vaclav Havel, Juraj Galeta, Jonathan A. Javitch, Susruta Majumdar
  • KRATOM OPIOID DERIVATIVES FOR THE TREATMENT OF ALCOHOL USE DISORDER
    Publication number: 20230250098
    Abstract: In some aspects, the present disclosure provides compounds of the formula: wherein the variables are as defined herein. In some embodiments, these compounds may be used to reduce the consumption of alcohol in a patient. These compounds may be used in treat or prevent alcoholism or an alcohol abuse disorder and show an improved pharmaceutical profile relative to other commonly used compounds.
    Type: Application
    Filed: October 4, 2022
    Publication date: August 10, 2023
    Applicants: University of Health Sciences & Pharmacy in St. Louis, Purdue Research Foundation, The Trustees of Columbia University in the City of New York
    Inventors: Susruta MAJUMDAR, Richard M. VAN RIJN, Soumen CHAKRABORTY, Balazs VARGA, Anna M. GUTRIDGE, Dalibor SAMES
  • G-protein biased opioid receptor agonist/analgesics with reduced arrestin recruitment
    Patent number: 11613547
    Abstract: In some aspects, the present disclosure provides compounds of the formula: wherein the variables are as defined herein. In some embodiments, these compounds may be used to reduce the pain of a patient. These compounds may be used in pain relief and show an improved pharmaceutical profile relative to other commonly used opiates and opioid derivatives.
    Type: Grant
    Filed: July 8, 2020
    Date of Patent: March 28, 2023
    Assignees: University of Health Sciences & Pharmacy in St. Louis, University of Southern California, The University of North Carolina at Chapel Hill, Memorial Sloan Kettering Cancer Center, University of Florida Research Foundation, Incorporated
    Inventors: Susruta Majumdar, Vsevolod Katritch, Bryan Roth, Jay McLaughlin, Saheem Zaidi, Gavril W. Pasternak, Rajendra Uprety
  • DEUTERATED MITRAGYNINE ANALOGS AS SAFER OPIOID MODULATORS IN THE MITRAGYNINE CLASS
    Publication number: 20220135564
    Abstract: The present invention provides a compound having the structure: or a pharmaceutically acceptable salt or ester thereof, and methods of using the compound to treat pain, depressive disorders, mood disorders, anxiety disorders, opioid use disorder, and opioid withdrawal symptoms.
    Type: Application
    Filed: January 30, 2020
    Publication date: May 5, 2022
    Applicants: The Trustees of Columbia University in the City of New York, The Research Foundation for Mental Hygiene, Inc., Sloan-Kettering Institute for Cancer Research
    Inventors: Andrew C. Kruegel, Dalibor Sames, Jonathan A. Javitch, Susruta Majumdar
  • MITRAGYNINE ANALOGS AND USES THEREOF
    Publication number: 20220024923
    Abstract: Described herein are compounds of Formulae (I?)-(II?), compounds of Formulae (I)-(II) and pharmaceutically acceptable salts thereof. Compounds of the present invention are useful for modulating opioid receptor activity. The provided compounds may have both agonistic and antagonistic effect on one or more opioid receptors. Methods of using the compounds for treating or managing pain are also described.
    Type: Application
    Filed: June 24, 2021
    Publication date: January 27, 2022
    Applicant: Memorial Sloan-Kettering Cancer Center
    Inventors: Gavril Pasternak, Susruta Majumdar, Rashad Karimov, Andras Varadi
  • Ligands of the mu, kappa, and delta opioid receptors
    Patent number: 11213518
    Abstract: Ligands of the mu, kappa, and delta opioid receptors and methods of using them are disclosed. In particular, the invention relates to the discovery of new opioid receptor ligands based on molecular dynamics simulations of conformational states of the ? opioid receptor and the use of the identified opioid receptor ligands as analgesics, anti-diarrheal agents, and overdose reversal agents.
    Type: Grant
    Filed: November 14, 2018
    Date of Patent: January 4, 2022
    Assignees: The Board of Trustees of the Leland Stanford Junior University, Memorial Sloan-Kettering Cancer Center
    Inventors: Evan N. Feinberg, Vijay S. Pande, Susruta Majumdar, Gavril Pasternak
  • Mitragynine analogs and uses thereof
    Patent number: 11046692
    Abstract: Described herein are compounds of Formulae (I?)-(II?), compounds of Formulae (I)-(II) and pharmaceutically acceptable salts thereof. Compounds of the present invention are useful for modulating opioid receptor activity. The provided compounds may have both agonistic and antagonistic effect on one or more opioid receptors. Methods of using the compounds for treating or managing pain are also described.
    Type: Grant
    Filed: April 29, 2016
    Date of Patent: June 29, 2021
    Assignee: Memorial Sloan-Kettering Cancer Center
    Inventors: Gavril Pasternak, Susruta Majumdar, Rashad Karimov, Andras Varadi
  • MITRAGYNINE ANALOGS FOR THE TREATMENT OF PAIN, MOOD DISORDERS AND SUBSTANCE USE DISORDERS
    Publication number: 20210179619
    Abstract: The present invention provides a compound having the structure: or a pharmaceutically acceptable salt or ester thereof, and a method of treating a subject afflicted with pain, a depressive disorder, a mood disorder or an anxiety disorder by administering the compound to the subject.
    Type: Application
    Filed: February 16, 2021
    Publication date: June 17, 2021
    Applicants: The Trustees of Columbia University in the City of New York, The Research Foundation for Mental Hygiene, Inc., Sloan-Kettering Institute for Cancer Research
    Inventors: Andrew C. Kruegel, Dalibor Sames, Srijita Bhowmik, Vaclav Havel, Juraj Galeta, Jonathan A. Javitch, Susruta Majumdar
  • G-PROTEIN BIASED OPIOID RECEPTOR AGONIST/ANALGESICS WITH REDUCED ARRESTIN RECRUITMENT
    Publication number: 20210061814
    Abstract: In some aspects, the present disclosure provides compounds of the formula: wherein the variables are as defined herein. In some embodiments, these compounds may be used to reduce the pain of a patient. These compounds may be used in pain relief and show an improved pharmaceutical profile relative to other commonly used opiates and opioid derivatives.
    Type: Application
    Filed: July 8, 2020
    Publication date: March 4, 2021
    Applicants: St. Louis College of Pharmacy, University of Southern California, The University of North Carolina at Chapel Hill, Memorial Sloan Kettering Cancer Center, University of Florida Research Foundation, Incorporated
    Inventors: Susruta MAJUMDAR, Vsevolod KATRITCH, Bryan ROTH, JAY MCLAUGHLIN, Saheem ZAIDI, Gavril W. PASTERNAK, Rajendra UPRETY
  • Ligands of the Mu, Kappa, and Delta Opioid Receptors
    Publication number: 20200345715
    Abstract: Ligands of the mu, kappa, and delta opioid receptors and methods of using them are disclosed. In particular, the invention relates to the discovery of new opioid receptor ligands based on molecular dynamics simulations of conformational states of the ? opioid receptor and the use of the identified opioid receptor ligands as analgesics, anti-diarrheal agents, and overdose reversal agents.
    Type: Application
    Filed: November 14, 2018
    Publication date: November 5, 2020
    Inventors: Evan N. Feinberg, Vijay S. Pande, Susruta Majumdar, Gavril Pasternak
  • 6-amido derivatives of 4,5A-epoxymorphinans for treatment of pain
    Patent number: 10150775
    Abstract: Compounds of formula: in which R4 is chosen from substituted phenyl, optionally substituted naphthylene, optionally substituted anthracene and optionally substituted aromatic heterocycle, are useful as analgesics.
    Type: Grant
    Filed: August 8, 2017
    Date of Patent: December 11, 2018
    Assignee: Sloan-Kettering Institute for Cancer Research
    Inventors: Gavril Pasternak, Susruta Majumdar
  • MITRAGYNINE ANALOGS AND USES THEREOF
    Publication number: 20180134708
    Abstract: Described herein are compounds of Formulae (I?)-(II?), compounds of Formulae (I)-(II) and pharmaceutically acceptable salts thereof. Compounds of the present invention are useful for modulating opioid receptor activity. The provided compounds may have both agonistic and antagonistic effect on one or more opioid receptors. Methods of using the compounds for treating or managing pain are also described.
    Type: Application
    Filed: April 29, 2016
    Publication date: May 17, 2018
    Applicant: Memorial Sloan-Kettering Cancer Center
    Inventors: Gavril Pasternak, Susruta Majumdar, Rashad Karimov, Andras Varadi
  • 6-AMIDO DERIVATIVES OF 4,5A-EPOXYMORPHINANS FOR TREATMENT OF PAIN
    Publication number: 20180057504
    Abstract: Compounds of formula: in which R4 is chosen from substituted phenyl, optionally substituted naphthylene, optionally substituted anthracene and optionally substituted aromatic heterocycle, are useful as analgesics.
    Type: Application
    Filed: August 8, 2017
    Publication date: March 1, 2018
    Applicant: Sloan-Kettering Institute for Cancer Research
    Inventors: Gavril Pasternak, Susruta Majumdar
  • 6-amido derivatives of 4, 5-a epoxymorphinans for the treatment of pain
    Patent number: 9725457
    Abstract: Compounds of formula: in which R4 is chosen from substituted phenyl, optionally substituted naphthylene, optionally substituted anthracene and optionally substituted aromatic heterocycle, are useful as analgesics.
    Type: Grant
    Filed: May 19, 2014
    Date of Patent: August 8, 2017
    Assignee: Sloan-Kettering Institute for Cancer Research
    Inventors: Gavril Pasternak, Susruta Majumdar
  • 6-AMIDO DERIVATIVES OF 4, 5-a EPOXYMORPHINANS FOR THE TREATMENT OF PAIN
    Publication number: 20140255308
    Abstract: Compounds of formula: in which R4 is chosen from substituted phenyl, optionally substituted naphthylene, optionally substituted anthracene and optionally substituted aromatic heterocycle, are useful as analgesics.
    Type: Application
    Filed: May 19, 2014
    Publication date: September 11, 2014
    Applicant: MEMORIAL SLOAN-KETTERING CANCER CENTER
    Inventors: Gavril Pasternak, Susruta Majumdar
  • 6-AMIDO DERIVATIVES OF 4, 5-a EPOXYMORPHINANS FOR THE TREATMENT OF PAIN
    Publication number: 20130289060
    Abstract: Compounds of formula: in which R4 is chosen from substituted phenyl, optionally substituted naphthylene, optionally substituted anthracene and optionally substituted aromatic heterocycle, are useful as analgesics.
    Type: Application
    Filed: October 19, 2011
    Publication date: October 31, 2013
    Applicant: MEMORIAL SLOAN-KETTERING CANCER CENTER
    Inventors: Gavril Pasternak, Susruta Majumdar